Please read before use --

Instruction Video

Ver.2

Check before Use

Easy! Rapid! Detection of novel coronavirus antibodies (IgG) in blood samples.

QuaResearch COVID-19 IgG LF [Instructions for Use]

CELLSPECT

Significance of Measurement

This kit is intended for a research use in detecting human IgG antibodies against nucleocapsid protein of SARS-CoV-2 as the causative virus of COVID-19. There are two different methods to detect a virus infection, one is detecting virus itself like PCR methods and an other is detecting antibodies (IgG, IgM, IgA, etc.) produced after virus infection. An immuneresponse to COVID-19 is unclear, however, it was reported that IgM had not always produced in all patients. On the other hand, IgG had been detected in 60 - 80% of the patients in 10 days, and in most of the patients in 14 days after symptom onset. Further research and analysis are required for an immune reaction against SARS-CoV-2, though many cases are reported that amount of IgG against SARS-CoV-2 had been kept in 30 days after symptom onset.

Measuring Principles



the blood

7

The blood volume is approximately 10 μL from the tip of the sampler to the cut. At least half full of blood is required for testing



The illustration is an image of the product. Product appearance is subject to change without notice.

QuaResearch COVID-19 IgG LF [Instruction for Use]

Scientific Information (Antibody Titer with ELISA Method)

Non-parametric statistical analysis in antibody titers 15 - 21 days after symptom onset

p < 0.001antibody titer (with ELISA method) negative positive group group



positive percent value: 100%, negative percent value: 92%

false-positive rate: 0%, false-negative rate: 13%

Properties of QuaResearch IgG LF

sensitivity: 87%, specificity: 100%

Relationship between sensitivity of ELISA method and the days after symptom onset



ROC analysis as IgG antibody marker (ELISA method) sensitivity: 88%, specificity: 99% positive percent value: 99%, negative percent value: 97% false-positive rate: 0.2%, false-negative rate: 12%

area under the curve: 0.96 ~ ~ ~ ~ ~

0.007

(95% 00	nindence i	nterval: 0	.941 - 0.987)					
		positive group	negative group	total	_			positive group	negative group
lgG titer	positive negative	128	1	129	_	QuaResearch IgG LF	positive negative	20	0
		18	494	512				3	36
	total	146	495	641	-		total	23	36

Please check the followings before use

[Specimen Sampling]

- Apply the collected specimen to the sample well of the test stick immediately. Needed but not supplied materials:
- lancet (finger prick), adhesive plaster, disinfectant wipe, hemostatic gauze. [Operation]
- Perform this test in accordance with the procedure indicated in this manual.
- · Do NOT apply buffer before the specimen application.
- · This kit is designed for blood testing, but not for other type of specimen.
- This kit is available only for the designated purpose.
- · Use the buffer provided with the test stick.

[Oth ers]

- · Do not use this product for diagnostic and therapeutic treatment, as it is not an in vitro diagnostic medical device.
- · Users of this product are at their own risk and we are not responsible for any damage

or inconvenience caused by it.

Keep away from unrelated persons.

[Reference]

- 1.) Kei-ichi Hiramatsu, Standard Microbiology, 11th Edition, Igaku-Shoin (2012)
- 2.) Anu Haveri , "Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland," January to February 2020, Eurosurveillance. Volume 25, Issue 11, 19, Mar 2020.

Test

San

Buf

Saf

Inst

- 3.) Wanbing Liu, "Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2", J Clin Microbiol. 2020 Mar 30.
- 4.) Li Guo, "Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)", Clin Infect Dis. 2020 Mar 21.
- 5.) Juanjuan Zhao, "Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019", Clin Infect Dis. 2020 Mar 21.
- 6.) Grzelak et al, "SARS-CoV-2 Serological Analysis of COVID-19 Hospitalized Patients, Pauci-Symptomatic Individuals and Blood Donors". (Infectious Diseases (except HIV/AIDS), 24 April 2020)
- 7.) Liu et al, "Evaluation of Nucleocapsid and Spike Protein-Based ELISAs for Detecting Antibodies against SARS-CoV-2", Journal of Clinical Microbiology, 2020, JCM.00461-20, jcm;JCM.00461-20v1
- 8.) Sun et al, "Kinetics of SARS-CoV-2 Specific IgM and IgG Responses in COVID-19 Patients", Emerging Microbes & Infections, 9.1 (2020), 940-48

Manufacturer and Seller: Cellspect Co., Ltd. Address: 2-4-23 Kitaiioka, Morioka, Iwate 020-0857 URL: https://www.cellspect.com

Contact us: Cellspect Co., Ltd. TEL: +81 (0)19-681-2088 e-mail: st_support@cellspect.com Reception time: 9:00-17:00 (Except weekends and holidays) X We support the utilization and research with this product, but not for purposes other than intended.

In case you find any SARS-CoV-2 positive specimen in your research. please handle it properly according to the regulations of your facilities and competent authorities.

Specification

Product Name QuaResearch COVID-19 IgGLF CAT Code ERCGLF101(10test/kit) Measurement Principle Imm unochromatography Specimen Whole blood, serum, plasma Specimen Volume 10 µL Measurement Time 15 minutes 2 - 25°C Storage Temperature 12 months after manufacture date Expiration Date

		Kit Contei			
	【10 tests/kit】				
Stick	:	10			
npler	:	10			
fer	:	10			
ety Data Sheet	:	1			
ructions for Use	:	1			

nts